UroGen Pharma
URGN
63 hedge funds and large institutions have $413M invested in UroGen Pharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 15 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.07% less ownership
Funds ownership: 62.61% → 59.54% (-3.1%)
11% less funds holding
Funds holding: 71 → 63 (-8)
12% less capital invested
Capital invested by funds: $469M → $413M (-$55.9M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
+$10.7M |
| 2 |
BlackRock
New York
|
+$8.88M |
| 3 |
HCM
Highline Capital Management
New York
|
+$5.83M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$4.01M |
| 5 |
DG
Delek Group
Herzliya,
Israel
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$7.45M |
| 2 |
Millennium Management
New York
|
-$5.55M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$928K |
| 4 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
-$860K |
| 5 |
Renaissance Technologies
New York
|
-$793K |
URGN Hedge Fund Activity: Q4 2018 in Review
63 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2018, worth a combined $413M — down 12% from $469M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of URGN and 9 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 25 added.
The largest buyer was Wildcat Capital Management, adding an estimated $10.7M. The largest seller was Meitav Investment House, cutting an estimated $7.45M.
- 63 institutional investors held UroGen Pharma (URGN) as of Q4 2018, down from 71 in Q3 2018.
- Funds reported $413M of UroGen Pharma stock for Q4 2018, down 12% quarter-over-quarter.
- 9 funds opened new UroGen Pharma positions in Q4 2018 and 15 closed out, a net change of -6 holders.
- The largest UroGen Pharma buyer in Q4 2018 was Wildcat Capital Management, an estimated $10.7M added.
- The largest UroGen Pharma seller in Q4 2018 was Meitav Investment House, an estimated $7.45M sold.
Based on aggregated 13F filings for Q4 2018.